Bristol-Myers Squibb Board of Directors Establish Science and Technology Committee of the Board
NEW YORK, Sept. 11 /PRNewswire-FirstCall/ -- Today, the Bristol-Myers Squibb (NYSE:BMY) Board of Directors announced that it has formed a Science and Technology Board Committee of the Board, which will include Directors with a scientific, medical or technology background.
Laurie H. Glimcher, M.D., a distinguished professor of Immunology at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School and a member of the Board since 1997, will chair the committee. The other members of the committee are recently elected Board members Vicki Sato, Ph.D, who is currently a professor of management practice at the Harvard Business School and a professor of molecular and cell biology at Harvard University, and R. Sanders Williams, M.D., Dean of Duke University School of Medicine, who was elected to the Board today.
In addition to naming Dr. Glimcher the chair of the Science and Technology Committee, the Board also named James M. Cornelius, former Chairman of Guidant Corporation and former Chief Financial Officer of Eli Lilly and Company, as chair of the Audit Committee. Lewis Campbell, President and Chief Executive Officer of Textron Inc., will remain the chair of the Compensation and Management Development Committee and Robert E. Allen, former Chairman and Chief Executive Officer of AT&T, will remain the chair of the Committee on Directors and Corporate Governance.
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
Source: Bristol-Myers Squibb
CONTACT: Media: Jeff Macdonald, Communications, +1-212-546-4824, jeffrey.macdonald@bms.com, or Investors: John Elicker, Investor Relations,
+1-212-546-3775, john.elicker@bms.com, both of Bristol-Myers Squibb
Web site: http://www.bms.com/
